BR112019004684A2 - combinação de agonistas de fxr - Google Patents

combinação de agonistas de fxr

Info

Publication number
BR112019004684A2
BR112019004684A2 BR112019004684A BR112019004684A BR112019004684A2 BR 112019004684 A2 BR112019004684 A2 BR 112019004684A2 BR 112019004684 A BR112019004684 A BR 112019004684A BR 112019004684 A BR112019004684 A BR 112019004684A BR 112019004684 A2 BR112019004684 A2 BR 112019004684A2
Authority
BR
Brazil
Prior art keywords
fxr agonist
agonist combination
fxr
combination
farnesoid
Prior art date
Application number
BR112019004684A
Other languages
English (en)
Inventor
Bauer Andreas
Laffitte Bryan
Mueller Patrick
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112019004684A2 publication Critical patent/BR112019004684A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção refere-se a composições farmacêuticas compreendendo um agonista do receptor farnesóide x (fxr) e outro agente terapêutico, em particular para o tratamento ou prevenção de doenças ou distúrbios hepáticos.
BR112019004684A 2016-09-14 2017-09-12 combinação de agonistas de fxr BR112019004684A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662394446P 2016-09-14 2016-09-14
PCT/IB2017/055503 WO2018051230A1 (en) 2016-09-14 2017-09-12 Combination of fxr agonists

Publications (1)

Publication Number Publication Date
BR112019004684A2 true BR112019004684A2 (pt) 2019-05-28

Family

ID=60043251

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019004684A BR112019004684A2 (pt) 2016-09-14 2017-09-12 combinação de agonistas de fxr

Country Status (23)

Country Link
US (1) US20210290610A1 (pt)
EP (1) EP3512558A1 (pt)
JP (1) JP6878596B2 (pt)
KR (1) KR102218498B1 (pt)
CN (1) CN109689105A (pt)
AR (1) AR109652A1 (pt)
AU (2) AU2017328999B2 (pt)
BR (1) BR112019004684A2 (pt)
CA (1) CA3036760A1 (pt)
CL (1) CL2019000625A1 (pt)
CO (1) CO2019002245A2 (pt)
CR (1) CR20190125A (pt)
EC (1) ECSP19016844A (pt)
IL (1) IL264628A (pt)
JO (1) JOP20190040A1 (pt)
MX (1) MX2019003021A (pt)
PE (1) PE20190972A1 (pt)
PH (1) PH12019500326A1 (pt)
RU (1) RU2019110780A (pt)
SG (1) SG11201900651PA (pt)
TW (1) TW201811372A (pt)
WO (1) WO2018051230A1 (pt)
ZA (1) ZA201900528B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201907084VA (en) * 2017-02-24 2019-09-27 Genfit Pharmaceutical compositions for combination therapy
US20210186950A1 (en) 2018-05-31 2021-06-24 Novartis Ag Combinations comprising tropifexor and cenicriviroc
AU2020312734A1 (en) * 2019-07-18 2022-01-20 Enyo Pharma Improved treatment using EYP001
EP4076455A1 (en) * 2019-12-20 2022-10-26 Novartis AG Combination treatment of liver diseases using integrin inhibitors
CN112402430A (zh) * 2020-12-11 2021-02-26 大连医科大学 泽泻醇b-23-醋酸酯在预防和治疗急性肾损伤中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987121B2 (en) * 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
PE20110831A1 (es) * 2008-11-26 2011-11-20 Pfizer 3-aminociclopentanocarboxamidas como moduladores del receptor de quimiocina
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
NZ719078A (en) * 2013-11-05 2018-07-27 Novartis Ag Compositions and methods for modulating farnesoid x receptors
JP2017510572A (ja) * 2014-03-13 2017-04-13 ソーク インスティチュート フォー バイオロジカル スタディーズ Ｆｘｒアゴニストならびに作製および使用のための方法
KR20170066418A (ko) * 2014-09-12 2017-06-14 토비라 쎄라퓨틱스, 인크. 섬유증의 치료를 위한 세니크리비록 병용 요법
RU2017125365A (ru) * 2014-12-18 2019-01-21 Новартис Аг Производные азабициклооктана в качестве агонистов fxr для применения при лечении заболеваний печени и желудочно-кишечных заболеваний
JP6941109B2 (ja) * 2016-02-22 2021-09-29 ノバルティス アーゲー Ｆｘｒアゴニストを使用するための方法

Also Published As

Publication number Publication date
KR102218498B1 (ko) 2021-02-22
CL2019000625A1 (es) 2019-05-17
WO2018051230A1 (en) 2018-03-22
JOP20190040A1 (ar) 2019-03-10
RU2019110780A3 (pt) 2020-11-30
JP6878596B2 (ja) 2021-05-26
JP2019526644A (ja) 2019-09-19
ZA201900528B (en) 2021-06-30
AU2017328999B2 (en) 2019-12-19
CR20190125A (es) 2019-06-04
EP3512558A1 (en) 2019-07-24
AU2020201980A1 (en) 2020-04-09
MX2019003021A (es) 2019-09-26
AR109652A1 (es) 2019-01-09
TW201811372A (zh) 2018-04-01
AU2017328999A1 (en) 2019-02-21
PE20190972A1 (es) 2019-07-09
ECSP19016844A (es) 2019-03-29
KR20190044666A (ko) 2019-04-30
CA3036760A1 (en) 2018-03-22
PH12019500326A1 (en) 2019-11-11
CN109689105A (zh) 2019-04-26
CO2019002245A2 (es) 2019-05-31
SG11201900651PA (en) 2019-04-29
IL264628A (en) 2019-02-28
US20210290610A1 (en) 2021-09-23
RU2019110780A (ru) 2020-10-15

Similar Documents

Publication Publication Date Title
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
BR112019004684A2 (pt) combinação de agonistas de fxr
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
BR112019005985A2 (pt) composições de combinação compreendendo agonistas de fxr para tratar ou prevenir uma doença ou distúrbio fibrótico, cirrótico
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
MA40240A (fr) Composés hétéroaryle d'inhibition de la kinase
IL255203B (en) Topical pharmaceutical emulsion compositions comprising 3,5-dihydroxy-4-isopropyl-trans-stilbene and use thereof in the treatment or prophylaxis of dermatological conditions or disorders
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
MX369474B (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
BR112017023425A2 (pt) combinações terapêuticas de terapias antivirais e anti-inflamatórias
BR112018000568A2 (pt) antagonistas do receptor 5-ht6 para uso no tratamento da doença de alzheimer com apatia como comorbidade
BR112019025478A8 (pt) Combinação de regorafenib e inibidores de pd-1/pd-l1(2) para tratamento de câncer
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2687 DE 05-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.